SLNO Q4 2017 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$735M+258877.1% YoY

Gross Profit

-$85M-11.6% margin

Operating Income

-$5M-0.7% margin

Net Income

-$5M-0.7% margin

EPS (Diluted)

$-3.86

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$5M

Stock-Based Comp.

$25,031

Balance Sheet

Total Assets

$39M

Total Liabilities

$12M

Stockholders' Equity

$27M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$735M	$283,788	+258877.1%
Gross Profit	-$85M	$61,482	-138190.8%
Operating Income	-$5M	-$3M	-75.9%
Net Income	-$5M	-$3M	-92.3%